These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27288180)

  • 1. Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
    Mowafy S; Galanis A; Doctor ZM; Paranal RM; Lasheen DS; Farag NA; Jänne PA; Abouzid KA
    Bioorg Med Chem; 2016 Aug; 24(16):3501-12. PubMed ID: 27288180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
    Qin X; Li Z; Yang L; Liu P; Hu L; Zeng C; Pan Z
    Bioorg Med Chem; 2016 Jul; 24(13):2871-2881. PubMed ID: 27234887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.
    Hamed MM; Abou El Ella DA; Keeton AB; Piazza GA; Abadi AH; Hartmann RW; Engel M
    ChemMedChem; 2013 Sep; 8(9):1495-504. PubMed ID: 23847159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
    Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
    Zhang Y; Zhang Y; Liu J; Chen L; Zhao L; Li B; Wang W
    Bioorg Med Chem Lett; 2017 Apr; 27(7):1584-1587. PubMed ID: 28238614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
    Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR.
    Shao J; Chen E; Shu K; Chen W; Zhang G; Yu Y
    Bioorg Med Chem; 2016 Aug; 24(16):3359-70. PubMed ID: 27387355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
    Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
    Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
    Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
    Patel HM; Pawara R; Ansari A; Noolvi M; Surana S
    Bioorg Med Chem; 2017 May; 25(10):2713-2723. PubMed ID: 28366268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
    Zhou W; Liu X; Tu Z; Zhang L; Ku X; Bai F; Zhao Z; Xu Y; Ding K; Li H
    J Med Chem; 2013 Oct; 56(20):7821-37. PubMed ID: 24053674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel 4-arylamino-quinazoline derivatives as EGFR
    Gan W; Wang C; Pan Q; Li Y; Guo Y; Fan D; Peng Y; Rao Z; Xu S; Zheng P; Zhu W
    Bioorg Chem; 2022 Oct; 127():105994. PubMed ID: 35792314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
    Yu H; Li Y; Ge Y; Song Z; Wang C; Huang S; Jin Y; Han X; Zhen Y; Liu K; Zhou Y; Ma X
    Eur J Med Chem; 2016 Mar; 110():195-203. PubMed ID: 26829280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors.
    Tu Y; Wang C; Yang Z; Zhao B; Lai L; Yang Q; Zheng P; Zhu W
    Comput Struct Biotechnol J; 2018; 16():462-478. PubMed ID: 30455856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
    Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
    Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
    Ahmed MF; Magdy N
    Anticancer Agents Med Chem; 2017; 17(6):832-838. PubMed ID: 27671305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
    Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
    Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.
    Hoshi H; Hiyama G; Ishikawa K; Inageda K; Fujimoto J; Wakamatsu A; Togashi T; Kawamura Y; Takahashi N; Higa A; Goshima N; Semba K; Watanabe S; Takagi M
    Oncol Rep; 2017 Jan; 37(1):66-76. PubMed ID: 27840973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.